KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Receivables (2016 - 2025)

Novavax has reported Receivables over the past 14 years, most recently at $124.9 million for Q4 2025.

  • Quarterly results put Receivables at $124.9 million for Q4 2025, up 9.88% from a year ago — trailing twelve months through Dec 2025 was $124.9 million (up 9.88% YoY), and the annual figure for FY2025 was $124.9 million, up 9.88%.
  • Receivables for Q4 2025 was $124.9 million at Novavax, up from $39.4 million in the prior quarter.
  • Over the last five years, Receivables for NVAX hit a ceiling of $530.5 million in Q1 2022 and a floor of $39.4 million in Q3 2025.
  • Median Receivables over the past 5 years was $167.6 million (2022), compared with a mean of $203.2 million.
  • Biggest five-year swings in Receivables: surged 579.57% in 2021 and later crashed 74.54% in 2022.
  • Novavax's Receivables stood at $490.3 million in 2021, then crashed by 74.54% to $124.8 million in 2022, then soared by 152.96% to $315.7 million in 2023, then crashed by 63.99% to $113.7 million in 2024, then grew by 9.88% to $124.9 million in 2025.
  • The last three reported values for Receivables were $124.9 million (Q4 2025), $39.4 million (Q3 2025), and $231.7 million (Q2 2025) per Business Quant data.